TScan Therapeutics (TCRX) EBITDA Margin Growth (1y) (2021 - 2026)
TScan Therapeutics (TCRX) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,552.00 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1,049.00 |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | -129,757.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129,757.00 |
| Dec 31, 2025 | 459,119.00 |
| Sep 30, 2025 | 163,423.00 |
| Jun 30, 2025 | 510,795.00 |
| Mar 31, 2025 | 387,320.00 |
| Dec 31, 2024 | -522,443.00 |
| Sep 30, 2024 | -247,313.00 |
| Jun 30, 2024 | -558,279.00 |
| Mar 31, 2024 | -515,081.00 |
| Dec 31, 2023 | 30,638.00 |
| Sep 30, 2023 | -14,373.00 |
| Jun 30, 2023 | -40,588.00 |
| Mar 31, 2023 | 14,290.00 |
| Dec 31, 2022 | -10,494.00 |
| Sep 30, 2022 | 16,385.00 |
| Jun 30, 2022 | -92.00 |
| Mar 31, 2022 | -14,439.00 |
| Dec 31, 2021 | 48,477.00 |
| Sep 30, 2021 | 181,596.00 |